亚麻黄酮
伦瓦提尼
蛋白激酶B
医学
MAPK/ERK通路
癌症研究
药理学
细胞凋亡
信号转导
肝细胞癌
化学
索拉非尼
生物化学
作者
Che-Jui Yang,Meng-Hsuan Wu,Jung-Fa Tsai,Fei-Ting Hsu,Te-Chun Hsia,Kuo-Ching Liu,Yi Chun Kuo
出处
期刊:Anticancer Research
[Anticancer Research USA Inc.]
日期:2022-04-30
卷期号:42 (5): 2495-2505
被引量:4
标识
DOI:10.21873/anticanres.15728
摘要
AKT/ERK signaling transduction and anti-apoptosis effects have both been recognized as important mediators of hepatocellular carcinoma (HCC) progression. Targeting AKT/ERK signaling and mediating apoptosis may be beneficial for alleviating HCC growth. Lenvatinib, a tyrosine kinase inhibitor, has been approved by the FDA to treat HCC since 2018 as a monotherapy with limited efficacy. Amentoflavone, a biflavonoid in natural plants, has been shown to have the potential to suppress HCC progression in previous studies. Whether the combination of lenvatinib and amentoflavone may show superior HCC suppression is unclear.We used MTT, flow cytometry and western blotting assays to identify the role of lenvatinib and amentoflavone in both Hep3B and Huh7 cells.We found that amentoflavone enhances the suppressive effect of AKT/ERK signaling induced by lenvatinib and, thus, sensitizes HCC to lenvatinib. The intrinsic/extrinsic apoptosis pathways induced by lenvatinib were also boosted by amentoflavone.Amentoflavone sensitization of HCC to lenvatinib is associated with AKT/ERK inactivation and apoptosis induction.
科研通智能强力驱动
Strongly Powered by AbleSci AI